A new study adds to evidence which suggests treating breast cancer patients with sodium channel blockers could be a promising future treatment to prevent the spread of cancer during the gap between ...
Nat Clin Pract Neurol. 2008;4(3):159-169. Drug Primary clinical use Protective effect during administration in animal models? Effects of withdrawal in EAE Clinical study Phenytoin Treatment of ...
PHILADELPHIA -- An oral, non-addictive sodium channel blocker safely relieved moderate-to-severe acute pain following surgery, according to phase III data that could support regulatory approval.
Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to ...
Note: On January 30, 2025 the FDA approved the first-in-class non-opioid analgesic Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults. The novel drug reduces pain by ...
Much like a city, the body relies on electricity to power its functions. Electrical currents keep the heart beating on pace, relax and contract muscles, and flow from neuron to neuron. To modulate the ...
A new study on live tissue cells is the first to reveal how channels that allow sodium to enter into breast cancer cells enable tumours to grow and spread. The discovery adds to evidence which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback